-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Reiterates Outperform on Immunic, Maintains $45 Price Target

Benzinga·09/10/2026 13:09:02
语音播报
Wedbush analyst Martin Fan reiterates Immunic (NASDAQ:IMUX) with a Outperform and maintains $45 price target.